A composition for alleviating the symptoms of eczema of the skin, and methods of making and using the same

Abstract

The present application provides a kind of composition for relieving the symptoms of skin eczema, it is prepared from the following weight ratio of raw drug: dandelion extract 0.005-0.2 parts, gentian extract 0.004-0.01 parts, golden chamomile extract 0.005-0.4 parts, egg yolk oil 0.005-0.2 parts.The present application also provides the preparation method and use of the composition.The present application provides a natural safety, with anti-inflammatory moisturizing anti eczema cream, optimizes its natural ingredients to reduce the oral discomfort of traditional technology baby, the problem of external use irritation, meets the long-term demand of natural anti eczema, anti-inflammatory moisturizing.

Description

Technical Field

[0001] This invention relates to a composition for relieving symptoms of eczema. Background Technology

[0002] Infantile eczema, known in Traditional Chinese Medicine as "milk rash" or "fetal eczema," is a skin inflammation characterized by intense itching caused by various internal and external factors. Its etiology is complex, often resulting from the interaction of these factors. It is characterized by polymorphic lesions, primarily papules and vesicles, with a tendency to ooze, recurrent episodes, overlapping acute and chronic phases, and intense itching. The exact cause is often difficult to determine. Infant skin is characterized by a thin stratum corneum, fewer intercellular connections, and fewer melanosomes, resulting in greater transepidermal water loss than adults. It also has a weak skin barrier function and poor resistance to external factors. Oral medication is often uncooperative in infants, and absorption through the digestive tract is slow. Western medicine primarily uses topical corticosteroids, which offer significant short-term effects but are prone to relapse. Long-term use can lead to localized skin atrophy, pigmentation, and even steroid dependence. Therefore, developing a natural, safe, anti-inflammatory, moisturizing, and anti-eczema cream alternative is of great importance.

[0003] This infant eczema treatment cream is a skincare product that blends traditional herbal wisdom with modern dermatological technology. It's a gentle, natural approach to treating infant eczema, offering targeted care for their delicate skin. First, the cream contains natural herbal ingredients and nutrients with antibacterial, soothing, and anti-inflammatory properties. The active ingredients penetrate the skin's surface to relieve redness, itching, and other discomfort caused by eczema, reducing inflammation while replenishing moisture and nutrients, improving dryness, helping damaged skin gradually recover, and enhancing its own resistance. Second, the natural ingredients in this cream are gentler and will not irritate the delicate skin of infants, nor does it cause drug dependence. Third, compared to more complex eczema relief methods, this cream is convenient to use. Therefore, the development of a natural, safe, anti-inflammatory, moisturizing, and eczema-fighting cream, with optimized natural ingredients, reduces the inconvenience of oral administration and the irritation associated with traditional methods, meeting the long-term need for natural anti-eczema, anti-inflammatory, and moisturizing effects.

[0004] Infant eczema treatment cream is a skin care product for infants that combines traditional herbal care wisdom with modern dermatological technology. It is a gentle, natural care method that has an auxiliary therapeutic effect on infant eczema and is suitable for infants with eczema. Compared with oral medication, face cream is more convenient, easier for infants to accept, and has good stability. Dandelion extract has the effects of clearing heat and detoxifying, reducing swelling and dissipating nodules; golden chamomile extract is good at anti-allergy, soothing, and repairing the skin barrier; egg yolk oil has the effect of maintaining a moist healing environment and repairing the skin barrier (Jia Chuanchun, et al., Clinical efficacy of egg yolk oil, Shandong Journal of Traditional Chinese Medicine, 1999); gentian extract can clear heat and dry dampness, and has anti-inflammatory and antipruritic effects (Han Ping, et al., Anti-itch effect and mechanism of a gentian extract in dry skin, Fragrance and Cosmetics, June 2021); furthermore, egg yolk oil is also effective in moisturizing the skin. Studies have confirmed that preparations containing egg yolk oil can significantly increase the moisture content of the stratum corneum and reduce transepidermal water loss, demonstrating superior moisturizing and barrier-stabilizing effects (Sun Jinyuan, Feng Xiangqing, Chen Yiping, et al. Study on the effect of special care cream containing egg yolk oil on improving the skin barrier [J]. Guangdong Chemical Industry, 2025(14).). However, the above single ingredients have certain drawbacks when used alone: ​​dandelion is bitter and cold in nature, and its use alone can easily damage the spleen and stomach, and its extract has poor stability, and the active ingredients are easily degraded and ineffective; although golden chamomile is mild, the effective ingredients it contains, such as magnolol, are easily oxidized and discolored, and the skin care effect is difficult to last; egg yolk oil is greasy in texture, and its application alone does not feel good on the skin, and it is easy to stain clothes, affecting the user experience; the bitter and cold nature of gentian extract may irritate the delicate skin of infants and young children, and there is a risk of long-term use. The above single ingredients not only have the above-mentioned instability and irritation defects when used alone, but their effects are also difficult to coordinate, and they cannot simultaneously cover the multiple pathological links in the course of eczema, such as itching, inflammation, and barrier damage. Modern research on medication patterns also shows that the treatment of pediatric eczema often employs compound prescriptions to synergistically enhance efficacy (Li Jie, Zhang Ze, Wang Yongqiang, et al. Medication patterns of traditional Chinese medicine in the treatment of pediatric eczema based on data mining [J]. Journal of PLA Pharmacy, 2024, 37(4):330-333.). Therefore, it is necessary to develop a natural and safe face cream with anti-inflammatory, moisturizing, and anti-eczema properties, optimizing its natural ingredients to reduce the inconvenience of oral administration and external irritation for infants and young children caused by traditional techniques, and to meet the long-term demand for natural anti-eczema, anti-inflammatory, and moisturizing effects. Summary of the Invention

[0005] This invention provides a composition for relieving symptoms of eczema, a method for preparing the composition, and its uses.

[0006] This invention provides a composition for relieving symptoms of eczema, which is prepared from the following raw materials in the indicated weight ratios:

[0007] Dandelion extract 0.005-0.2 parts, gentian extract 0.004-0.01 parts, golden chamomile extract 0.005-0.4 parts, egg yolk oil 0.005-0.2 parts.

[0008] Preferably, it is prepared from the following raw materials in the indicated weight ratios:

[0009] Dandelion extract 0.1-0.2 parts, gentian extract 0.004-0.01 parts, golden chamomile extract 0.1-0.4 parts, egg yolk oil 0.005-0.2 parts.

[0010] More preferably, it is prepared from the following raw materials in the indicated weight ratios:

[0011] Dandelion extract 0.2 parts, gentian extract 0.01 parts, golden chamomile extract 0.2 parts, egg yolk oil 0.15 parts.

[0012] The composition is prepared as a topical preparation by using the active pharmaceutical ingredient as the active ingredient and adding pharmaceutically acceptable excipients or auxiliary ingredients.

[0013] The external preparations mentioned above include emulsions, solutions, liniments, lotions, ointments, creams, gels, pastes, and creams.

[0014] The excipients of the emulsion include a humectant, an aqueous matrix, and an oil matrix, and the excipients are:

[0015] The oil phase includes: 1.20 parts hydrogenated lecithin, 1.70 parts jojoba oil, 0.80 parts isopropyl palmitate, 0.40 parts glyceryl stearate, 0.35 parts stearyl alcohol, and 0.25 parts tocopherol;

[0016] The aqueous phase includes: 0.15 parts ceramide, 4.0 parts glycerol, 0.08 parts xanthan gum, 0.15 parts triethanolamine, 0.20 parts carbomer, 0.10 parts phenoxyethanol, 0.07 parts ethylhexylglycerin, 0.15 parts potassium sorbate, and 50 parts purified water;

[0017] The moisturizing agents include 0.0025 parts of recombinant humanized collagen and 0.25 parts of sodium hyaluronate;

[0018] The present invention also provides a method for preparing the composition for relieving symptoms of eczema, wherein the method for preparing the emulsion includes the following steps:

[0019] a. Preparation of aqueous phase: Weigh carbomer and glycerin into pure water, stir, and place in an 80℃ water bath to disperse carbomer for 30-50 minutes. Then weigh gentian extract, dandelion extract, golden chamomile extract, recombinant humanized collagen, and sodium hyaluronate and add them. Then add phenoxyethanol, ethylhexylglycerin, and potassium sorbate and place them in an 80℃ water bath to disperse them evenly. Then add xanthan gum, and finally add triethanolamine and ceramide. Place in an 80℃ high-temperature water bath to make the aqueous phase homogeneous.

[0020] b. Preparation of the oil phase: Weigh hydrogenated lecithin, jojoba oil, isopropyl palmitate, glyceryl stearate, stearyl alcohol, and tocopherol, and place them in an 80°C high-temperature water bath to melt them;

[0021] c. Mixing and emulsification: Slowly add the high-temperature oil phase to the high-temperature water phase while stirring at high speed (1000-2000 rpm), and slowly add egg yolk oil drop by drop, continuing to stir until it is completely emulsified.

[0022] Preferably, the emulsification time for step c is 8 minutes.

[0023] This invention provides the use of the described composition in the preparation of a topical medicine with anti-inflammatory, moisturizing, and anti-eczema effects.

[0024] The aforementioned topical medication is for treating infantile eczema, representing a gentle, natural, and adjunctive treatment approach. Firstly, the cream contains antibacterial, soothing, and anti-inflammatory natural herbal ingredients and nutrients that can penetrate the surface of the infant's skin, relieving discomfort such as redness, swelling, and itching caused by eczema, reducing skin inflammation, and simultaneously replenishing the skin with moisture and nutrients, enhancing its own resistance. Secondly, the natural ingredients in this infantile eczema treatment cream are gentler, will not irritate the delicate skin of infants, and do not cause drug dependence. Moreover, compared to more complex eczema relief methods, the cream is more convenient to use. Therefore, the development of a natural, safe, anti-inflammatory, moisturizing, and eczema-relieving cream, optimizing its natural ingredients to reduce the inconvenience of oral administration and the irritation associated with traditional techniques for infants, meets the long-term need for natural anti-eczema, anti-inflammatory, and moisturizing effects. Attached Figure Description

[0025] Figure 1 Photo of the prepared face cream. Detailed Implementation

[0026] The following are the sources of the raw and auxiliary materials used in this invention:

[0027] (1) Egg Yolk Oil: After boiling eggs in their shells at 94℃ for 15 minutes, the yolks were separated and placed in a beaker, then crushed into a fine powder using a glass rod. The fine yolk powder was spread evenly on an enamel plate (about 1.5 cm thick) and dried in a forced-air drying oven at 150℃ for 30 minutes to remove moisture and produce dried egg yolk powder. After the egg yolk powder cooled to room temperature (laboratory temperature 23.7℃), the dried egg yolk powder was transferred to a beaker, and 1000 mL of anhydrous ethanol was added for every 700 g of dried egg yolk powder to completely submerge the powder. The mixture was stirred with a glass rod to ensure full contact between the anhydrous ethanol and the egg yolk powder. The anhydrous ethanol turned yellow. The mixture was then filtered through gauze to obtain anhydrous ethanol containing egg yolk oil. 1000 mL of anhydrous ethanol was added to the egg yolk powder from which the egg yolk oil had been extracted. This process was repeated twice. The anhydrous ethanol containing egg yolk oil was lighter in color, indicating that most of the egg yolk oil had been extracted into the anhydrous ethanol. After three extractions and filtrations, approximately 2600 mL of anhydrous ethanol containing egg yolk oil was collected. The anhydrous ethanol containing egg yolk oil was separated using a rotary evaporator at 50 °C. After the ethanol was completely evaporated, the egg yolk oil was obtained. The ethanol was allowed to evaporate completely, and finally, a yellow and clear egg yolk oil was obtained.

[0028] (2) Gentian extract: The gentian extract used in this embodiment is a commercially available product (Shaanxi Panier Biotechnology Co., Ltd., batch number: PB250517, gentiopicroside content >98%), with a moisture content not exceeding 9.0%-16%; total ash not exceeding 7.0%, acid-insoluble ash not exceeding 3.0%-16%, and heavy metal (lead, arsenic, mercury, cadmium) content meeting the requirements of the "Cosmetic Safety Technical Specifications". It is an extract obtained by extracting, concentrating, and drying gentian rhizomes; or refer to Han Ping, Li Honghai, Ma Shijing, et al. Anti-itching effect of a gentian extract and its mechanism [J]. Fragrance, Flavor and Cosmetics, 2021, No.189(06):27-31;

[0029] (3) Golden Chamomile Extract: A simple extract can be purchased on the market (Shaanxi Baichuan Kangze Technology Co., Ltd. - Batch No.: BCSW250703-1); the total flavonoid content of the golden chamomile extract is not less than 2.5% (calculated as rutin, determined by UV-VIS method), the moisture content is not higher than 6.0%, and the heavy metal (lead, arsenic, mercury) content meets the requirements of the "Cosmetic Safety Technical Specifications";

[0030] (4) Dandelion extract: can be purchased on the market (Shaanxi Baichuan Kangze Biotechnology Co., Ltd., batch number: BCSW250715-1) with chicoric acid content not less than 0.04%, moisture content not more than 6.0% on a dried basis, and heavy metal content (lead, arsenic, mercury, cadmium) meeting the relevant requirements of the "Cosmetic Safety Technical Specifications"; or can be prepared by referring to the method described in Wu Ying, Liu Qing, Tang Wen, et al. Application of the compound of dandelion volatile oil and dandelion extract in cosmetics [J]. Fine Chemicals, 2022, 39(3): 562-568;

[0031] (5) Recombinant humanized collagen: available for purchase on the market (Jiangsu Jinpu Nuoan Biotechnology Co., Ltd.);

[0032] (6) Sodium hyaluronate: Available for purchase on the market (Bloomage Biotechnology Co., Ltd.).

[0033] Example 1: Preparation of an anti-inflammatory and anti-eczema face cream for infants and young children

[0034] Weigh 0.2g of carbomer and 4g of glycerin into pure water, stir, and place in an 80℃ water bath to disperse the carbomer for 50 minutes. Then weigh 0.004g of gentian extract, 0.005g of dandelion extract, 0.1g of golden chamomile extract, 0.0025g of recombinant humanized collagen, and 0.25g of sodium hyaluronate and add them to the water bath. Then add 0.1g of phenoxyethanol, 0.07g of ethylhexylglycerin, and 0.15g of potassium sorbate and place them in an 80℃ water bath to disperse them evenly. Then add xanthan gum, and finally add 0.15g of triethanolamine and 0.15g of ceramide. Place the water bath at 80℃ to make the aqueous phase homogeneous. Weigh out 1.2g of hydrogenated lecithin, 1.7g of jojoba oil, 0.8g of isopropyl palmitate, 0.4g of glyceryl stearate, 0.35g of stearyl alcohol, and 0.25g of tocopherol, and place them in an 80°C water bath to melt them. Slowly add the hot oil phase to the hot aqueous phase while stirring at high speed (1000-2000 rpm), and simultaneously slowly add 0.4g of egg yolk oil dropwise, continuing to stir until emulsification is complete (preferably 8 minutes).

[0035] Example 2: Preparation of face cream

[0036] The face cream was prepared according to the method in Example 1. The formula included: 0.1g dandelion extract, 0.004g gentian extract, 0.005g golden chamomile extract, 0.4g egg yolk oil, 0.0025g recombinant humanized collagen, and 0.25g sodium hyaluronate. The oil phase included 1.2g hydrogenated lecithin, 1.7g jojoba oil, 0.8g isopropyl palmitate, 0.4g glyceryl stearate, 0.35g stearyl alcohol, and 0.25g tocopherol. The aqueous phase included 0.15g ceramide, 4g glycerin, 0.08g xanthan gum, 0.15g triethanolamine, 0.2g carbomer, 0.1g phenoxyethanol, 0.07g ethylhexylglycerin, 0.15g potassium sorbate, and 50g purified water.

[0037] Example 3: Preparation of face cream

[0038] The face cream was prepared according to the method in Example 1. The formula included: 0.1g dandelion extract, 0.004g gentian extract, 0.4g golden chamomile extract, 0.005g egg yolk oil, 0.0025g recombinant humanized collagen, and 0.25g sodium hyaluronate. The oil phase included 1.2g hydrogenated lecithin, 1.7g jojoba oil, 0.8g isopropyl palmitate, 0.4g glyceryl stearate, 0.35g stearyl alcohol, and 0.25g tocopherol. The aqueous phase included 0.15g ceramide, 4g glycerin, 0.08g xanthan gum, 0.15g triethanolamine, 0.2g carbomer, 0.1g phenoxyethanol, 0.07g ethylhexylglycerin, 0.15g potassium sorbate, and 50g purified water.

[0039] Example 4: Preparation of face cream

[0040] The face cream was prepared according to the method in Example 1. The formula included: 0.15g of dandelion extract, 0.009g of gentian extract, 0.2g of golden chamomile extract, 0.15g of egg yolk oil, 0.0025g of recombinant humanized collagen, and 0.25g of sodium hyaluronate. The oil phase included 1.2g of hydrogenated lecithin, 1.7g of jojoba oil, 0.8g of isopropyl palmitate, 0.4g of glyceryl stearate, 0.35g of stearyl alcohol, and 0.25g of tocopherol. The aqueous phase included 0.15g of ceramide, 4g of glycerin, 0.08g of xanthan gum, 0.15g of triethanolamine, 0.2g of carbomer, 0.1g of phenoxyethanol, 0.07g of ethylhexylglycerin, 0.15g of potassium sorbate, and 50g of purified water.

[0041] Example 5: Preparation of face cream

[0042] The face cream was prepared according to the method in Example 1. The formula included: 0.2g of dandelion extract, 0.009g of gentian extract, 0.1g of golden chamomile extract, 0.2g of egg yolk oil, 0.0025g of recombinant humanized collagen, and 0.25g of sodium hyaluronate. The oil phase included 1.2g of hydrogenated lecithin, 1.7g of jojoba oil, 0.8g of isopropyl palmitate, 0.4g of glyceryl stearate, 0.35g of stearyl alcohol, and 0.25g of tocopherol. The aqueous phase included 0.15g of ceramide, 4g of glycerin, 0.08g of xanthan gum, 0.15g of triethanolamine, 0.2g of carbomer, 0.1g of phenoxyethanol, 0.07g of ethylhexylglycerin, 0.15g of potassium sorbate, and 50g of purified water.

[0043] Example 6: Preparation of face cream

[0044] The face cream was prepared according to the method in Example 1. The formula included: 0.2g dandelion extract, 0.01g gentian extract, 0.2g golden chamomile extract, 0.15g egg yolk oil, 0.0025g recombinant humanized collagen, and 0.25g sodium hyaluronate. The oil phase consisted of 1.2g hydrogenated lecithin, 1.7g jojoba oil, 0.8g isopropyl palmitate, 0.4g glyceryl stearate, 0.35g stearyl alcohol, and 0.25g tocopherol. The aqueous phase consisted of 0.15g ceramide, 4g glycerin, 0.08g xanthan gum, 0.15g triethanolamine, 0.2g carbomer, 0.1g phenoxyethanol, 0.07g ethylhexylglycerin, 0.15g potassium sorbate, and 50g purified water. The prepared face cream was as follows: Figure 1 As shown.

[0045] Example 7: Stability test of the face cream composition of the present invention

[0046] 1. Stability evaluation of face cream

[0047] 1.1 Sensory evaluation

[0048] Observe indoors and in non-direct sunlight conditions. Apply the sample to the skin and visually inspect it to observe its appearance, whether the color is bright, and whether there are any visible individual particles or bubbles.

[0049] 1.2 High Temperature Test

[0050] The sample was sealed with pharmaceutical-grade aluminum tubing and placed in a 40°C forced-air drying oven for 10 days. Samples were taken on the 5th and 10th days to observe whether the appearance of the preparation changed color and its viscosity changed.

[0051] 1.3 Cold Resistance Test

[0052] Place 5g of the Example 6 sample in a beaker, seal it, and put it in a -10℃ refrigerator. After 24 hours, take it out and let it return to room temperature. Visually observe whether there is any layering or discoloration.

[0053] 1.4 Centrifugation test

[0054] Three batches of samples were loaded into centrifuge tubes, weighed, and placed in a centrifuge. The tubes were centrifuged at 2500 rpm for 10 minutes to observe whether there was any oil-water separation.

[0055] 1.5 Results

[0056] Table 1 Results of face cream stability test

[0057]

[0058] The following efficacy tests demonstrate the beneficial effects of the present invention.

[0059] Experimental Example 1: Eczema Model Induction Experiment

[0060] 1. Preparation of face cream for blank control group

[0061] The face cream was prepared according to the method in Example 1. The formula consisted of: an oil phase comprising 1.2 parts hydrogenated lecithin, 1.7 parts jojoba oil, 0.8 parts isopropyl palmitate, 0.4 parts glyceryl stearate, 0.35 parts stearyl alcohol, and 0.25 parts tocopherol; and an aqueous phase comprising 0.15 parts ceramide, 4 g glycerin, 0.08 parts xanthan gum, 0.15 parts triethanolamine, 0.2 parts carbomer, 0.1 parts phenoxyethanol, 0.07 parts ethylhexylglycerin, 0.15 parts potassium sorbate, and 50 parts purified water.

[0062] 2. Positive control group

[0063] According to the eczema model induction experiment, only 0.1% hydrocortisone cream was applied.

[0064] 3. Model Group

[0065] Induction experiments were conducted using an eczema model, but no medication was administered.

[0066] 4. Normal group

[0067] Prepare 5 normal mice, without induction or drug administration.

[0068] 5. Experimental methods:

[0069] Fifty ICR mice were randomly divided into 10 groups of 5 mice each: blank control group, model group, positive control group, drug treatment group (including screening ratio, 6 groups of 5 mice each), and normal control group. The day before the experiment, 2cm × 2cm of hair was removed from the backs of the mice. Except for the normal control group, all other groups had 50ul of 5% DNCB acetone solution applied to the shaved areas on the backs on the first day of the experiment to induce sensitization. On the third day, the same method was used to reinforce the sensitization. On days 7, 10, and 13, except for the normal control group, the backs and right ears of the other mice were challenged with 50ul and 20ul of 0.5% DNCB acetone solution, respectively. An equal volume of physiological saline was applied to the left ear as a control. A total of 3 challenges were performed. Administer the first dose 1-2 hours after the initial challenge; continue daily administration on days 8 and 9; administer the dose after challenge on day 10; continue daily administration on days 11 and 12; administer the dose after challenge on day 13; after the last dose, wait 24-48 hours (i.e., day 15 or 16) before euthanizing and evaluating the animal. Assess back injury using the table below.

[0070] Table 2 Scoring Criteria for Severity of Eczema Lesions on the Back

[0071]

[0072] 6. Implementation Results:

[0073] Table 3. Experimental Results of Face Cream Examples

[0074]

[0075] Based on the cream color in Examples 1-10, and using efficacy as the evaluation index, the optimal dosage of the main ingredients was determined to be 0.2g of dandelion extract, 0.01g of gentian extract, 0.2g of golden chamomile extract, and 0.15g of egg yolk oil. All experimental data were statistically processed using GraphPad Prism software and expressed as X±SD. Analysis was performed using unpaired two-tailed t-tests or one-way ANOVA. "*" indicates a comparison with the model group, P<0.05; "**" indicates a comparison with the model group, P<0.01; "***" indicates a comparison with the model group, P<0.001; "****" indicates a comparison with the model group, P<0.0001.

[0076] Test Example 2: Synergistic effect test of the anti-eczema and anti-inflammatory effects of the cream composition of the present invention

[0077] The purpose of this experiment was to explore whether a face cream composition consisting of dandelion extract, egg yolk oil, golden chamomile, and gentian extract is superior to other single-ingredient drugs in terms of anti-inflammatory and anti-eczema effects. The experimental methods referenced those used in pharmacological studies of anti-eczema and anti-inflammatory drugs, investigating the superior anti-eczema and anti-inflammatory effects of face cream compositions with different ratios at equal dosages compared to single-ingredient drugs.

[0078] Blank control group: After eczema modeling, only matrix treatment was used;

[0079] Model control group: No medication was administered after eczema modeling;

[0080] Positive control group: After eczema modeling, clinically effective drugs (such as 0.1% hydrocortisone cream or tacrolimus ointment) were used.

[0081] Each single-drug group (4 groups): After modeling, dandelion extract, gentian extract, egg yolk oil, and golden chamomile extract were administered at a dose of 0.028.

[0082] The four-drug combination group (Group 1): Dandelion extract, gentian extract, egg yolk oil, and golden chamomile extract were mixed at a dose of 0.007, with a total dose of 0.007*4.

[0083] The four-drug combination group (2 groups): dandelion extract 0.01, gentian extract 0.0005, egg yolk oil 0.0075, golden chamomile extract 0.01, with a total dose of 0.028.

[0084] I. Laboratory Animals

[0085] ICR mice, male, 20-25g

[0086] II. Experimental Drugs and Reagents

[0087] DNCB (2,4-dinitrochlorobenzene), acetone solution, hydrocortisone cream

[0088] III. Modeling Methods

[0089] A preliminary experimental group was set up. A small number of mice (3 mice per group) were used to test different concentrations of DNCB (2%, 5%, and 7% for sensitization; 0.5%, 1%, and 2% for challenge). By observing the swelling of the back skin and ears, the optimal concentration for producing stable and moderately severe dermatitis was ensured.

[0090] Fifty ICR mice were randomly divided into 10 groups of 5 mice each: a blank control group (5 mice), a model group (5 mice), a positive control group, and four treatment groups (including screening groups, 5 mice per group). The day before the experiment, 2cm × 2cm of hair was removed from the backs of the mice. Except for the blank control group, all other groups had 50ul of 5% DNCB acetone solution applied to the shaved areas on the backs of the mice on the first day of the experiment to induce sensitization. On the third day, the same method was used to reinforce the sensitization. On days 7, 10, and 13, except for the blank control group, the backs and right ears of the other mice were challenged with 50ul and 20ul of 0.5% DNCB acetone solution, respectively, while the left ear was challenged with an equal volume of physiological saline as a control. A total of three challenges were performed. The first dose was administered 1-2 hours after the initial stimulation; daily administration continued on days 8 and 9; post-stimulation administration was administered on day 10; daily administration continued on days 11 and 12; post-stimulation administration was administered on day 13; after the last administration, animals were sacrificed and evaluated after 24-48 hours (i.e., day 15 or 16). (To avoid confusion between drug efficacy and self-healing effect). Following the experimental setup described above, holes were punched in the same location in both ears of mice using a 6 mm diameter mouse ear punch to obtain left and right ear flaps. The flaps were weighed, and ear swelling was calculated using the following formula: Ear swelling = Mass of left ear flap - Mass of right ear flap.

[0091] IV. Detection Indicators

[0092] Compare auricular skin lesion scores and swelling.

[0093] Test results

[0094] Table 4 Synergistic Efficacy Results

[0095]

[0096] Experimental Conclusions: All experimental data were statistically processed using GraphPad Prism software and expressed as mean ± SD. Analysis was performed using unpaired two-tailed t-tests or one-way ANOVA. "*" indicates a comparison with the model group (P < 0.05); "**" indicates a comparison with the model group (P < 0.01); "***" indicates a comparison with the model group (P < 0.001); "****" indicates a comparison with the model group (P < 0.0001). The model group mice showed significantly lower ear swelling compared to the control group, indicating successful model establishment. The equal-dose compound face cream group showed better inhibitory effects on eczema and back injury than the individual herbal groups compared to the model group. This demonstrates that the combined anti-eczema effect of dandelion extract, gentian extract, egg yolk oil, and golden chamomile extract is superior to that of individual herbs.

[0097] Test Example 3: Anti-inflammatory effect test of the face cream composition of the present invention

[0098] 1. Medication: Face cream

[0099] 2. Animals: Using the previously designed 10 experimental groups, ELISA samples will be obtained from animals in these groups, and sensitized and challenged with DNCB, as well as administered topical drugs daily.

[0100] 3. Procedure: Collect whole blood by enucleation of the eyeball or heart. Allow to stand, then centrifuge (3000 rpm, 15 min, 4°C). Carefully aspirate the supernatant serum and aliquot it into EP tubes. Detect systemic inflammatory factor levels (TNF-α, IL-4). Store at -80°C. Then slowly thaw at 4°C (transfer the serum sample to be tested from -80°C to 4°C overnight for slow thawing). After complete thawing, gently vortex at 4°C for 5-10 seconds. Briefly centrifuge (4°C, 5000-10000 rpm, 5 min), then use a pipette to aspirate the clear serum supernatant from the middle of the EP tube and add it directly to the pre-coated wells of the ELISA kit.

[0101] 4. Test Results

[0102] Table 5 Results of anti-inflammatory effects

[0103]

[0104] Experimental Conclusion: 0.2:0.01:0.2:0.15 Example 6: Compared with the model group, the compound face cream group showed significantly lower TNF-α and IL-4 concentrations, and its anti-inflammatory effect was superior to other compound groups. This proves that the compound face cream has an anti-inflammatory effect. All experimental data were statistically processed using GraphPad Prism software and are expressed as X±SD. Analysis was performed using unpaired two-tailed t-tests or one-way ANOVA. "ns" indicates a comparison with the model group, P>0.05, no significant difference; "*" indicates a comparison with the model group, P<0.05; "**" indicates a comparison with the model group, P<0.01; "***" indicates a comparison with the model group, P<0.001.

Claims

1. A composition for relieving symptoms of eczema, characterized in that: It is prepared from the following raw materials in the indicated weight ratios: Dandelion extract 0.005-0.2 parts, gentian extract 0.004-0.01 parts, golden chamomile extract 0.005-0.4 parts, egg yolk oil 0.005-0.2 parts.

2. The composition for relieving symptoms of eczema according to claim 1, characterized in that: It is prepared from the following raw materials in the indicated weight ratios: Dandelion extract 0.1-0.2 parts, gentian extract 0.004-0.01 parts, golden chamomile extract 0.1-0.4 parts, egg yolk oil 0.005-0.2 parts.

3. The composition for relieving symptoms of eczema according to claim 2, characterized in that: It is prepared from the following raw materials in the indicated weight ratios: Dandelion extract 0.2 parts, gentian extract 0.01 parts, golden chamomile extract 0.2 parts, egg yolk oil 0.15 parts.

4. The composition for relieving symptoms of eczema according to any one of claims 1-3, characterized in that: The composition is prepared as a topical preparation by using the active pharmaceutical ingredient as the active ingredient and adding pharmaceutically acceptable excipients or auxiliary ingredients.

5. The composition for relieving symptoms of eczema according to claim 4, characterized in that: The aforementioned topical preparations include emulsions, solutions, liniments, lotions, ointments, creams, gels, pastes, and creams.

6. The composition for relieving symptoms of eczema according to claim 5, characterized in that: The topical preparation is an emulsion, and its excipients include a moisturizer, an aqueous matrix, and an oil matrix. The excipients of the moisturizer include: recombinant humanized collagen and sodium hyaluronate, in a weight ratio of: 0.001-0.0025 parts of recombinant humanized collagen and 0.15-0.25 parts of sodium hyaluronate; Preferably, the moisturizer comprises 0.0025 parts of recombinant humanized collagen and 0.25 parts of sodium hyaluronate; The oil phase comprises: 0.4-1.5 parts hydrogenated lecithin, 0.15-1.7 parts jojoba oil, 0.25-0.8 parts isopropyl palmitate, 0.4-1 parts glyceryl stearate, 0.35-0.4 parts stearyl alcohol, and 0.2-0.25 parts tocopherol; The aqueous phase comprises 0.15-0.2 parts ceramide, 3-4.5 parts glycerol, 0.075-0.7 parts xanthan gum, 0.15-0.2 parts triethanolamine, 0.15-0.5 parts carbomer, 0.1-0.15 parts phenoxyethanol, 0.05-0.1 parts ethylhexylglycerol, 0.075-0.15 parts potassium sorbate, and 47-75 parts purified water. Preferably, the oil phase comprises: 1.20 parts hydrogenated lecithin, 1.70 parts jojoba oil, 0.80 parts isopropyl palmitate, 0.40 parts glyceryl stearate, 0.35 parts stearyl alcohol, and 0.25 parts tocopherol; the aqueous phase comprises: 0.15 parts ceramide, 4.0 parts glycerol, 0.08 parts xanthan gum, 0.15 parts triethanolamine, 0.20 parts carbomer, 0.10 parts phenoxyethanol, 0.07 parts ethylhexylglycerin, 0.15 parts potassium sorbate, and 50 parts purified water.

7. A method for preparing a composition for relieving symptoms of eczema according to any one of claims 1-6, characterized in that: The method for preparing the emulsion includes the following steps: a. Preparation of the aqueous phase: Weigh carbomer and glycerin into pure water, stir, and place in an 80℃ water bath to disperse the carbomer for 30-50 minutes. Then weigh gentian extract, dandelion extract, golden chamomile extract, recombinant humanized collagen, and sodium hyaluronate and add them. Next, add phenoxyethanol, ethylhexylglycerin, and potassium sorbate to an 80℃ water bath and disperse them evenly. Then add xanthan gum, and finally add triethanolamine and ceramide. Place in an 80℃ high-temperature water bath to make the aqueous phase homogeneous. b. Preparation of the oil phase: Weigh hydrogenated lecithin, jojoba oil, isopropyl palmitate, glyceryl stearate, stearyl alcohol, and tocopherol, and place them in an 80°C high-temperature water bath to melt them; c. Mixing and emulsification: Slowly add the high-temperature oil phase to the high-temperature water phase while stirring at high speed (1000-2000 rpm), and slowly add egg yolk oil drop by drop, continuing to stir until it is completely emulsified.

8. The method for preparing the composition for relieving eczema symptoms according to claim 7, characterized in that: The emulsification time for step c is 8 minutes.

9. Use of the composition according to any one of claims 1-6 in the preparation of a medicament for treating eczema.

10. The use according to claim 9, characterized in that: The topical medication mentioned is for treating infantile eczema.

Images